ER-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positiv

Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics: Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00) Efficacy and safety of oral SERDs in patients with ER-positive metastatic breast cancer (13:26) Similarities and differences among available and investigational oral SERDs for ER-positive metastatic breast cancer (24:21) CME information and select publications